Storia in 2 fonti

Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor - DexCom (NASDAQ:DXCM)

FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time Glucose Monitoring.

Raccontata da

medpagetoday.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo5 h fa

Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor - DexCom (NASDAQ:DXCM)

FDA clears Dexcom Stelo OTC for children 2+ without insulin—first over-the-counter CGM for pediatric patients. Real-world evidence approval signals FDA acceleration for pediatric health-tech and TAM expansion as juvenile prediabetes rises.

originale

medpagetoday.com15 h fa

FDA Clears First OTC Continuous Glucose Monitor for Kids

Authorization of Stelo integrated CGM extends to children without diabetes as well

Leggi questa versione → originale

Timeline cronologica

lunedì 15 giugno 2026·medpagetoday.com
FDA Clears First OTC Continuous Glucose Monitor for Kids
Authorization of Stelo integrated CGM extends to children without diabetes as well
lunedì 15 giugno 2026·benzinga.com
Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor - DexCom (NASDAQ:DXCM)
FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time Glucose Monitoring.